FilingSEC EDGAR8-K
Prothena Announces Termination of PRX019 License Agreement Following BMS Development Halt
· SEC accepted
StageAgreement Termination
Filing content
Bristol Myers Squibb decided to halt development of PRX019, leading to the termination of the global license agreement with Prothena effective January 28, 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…